Direxion Healthcare Bull 3X

Eli Lilly and Company announces an additional $4.5 billion investment in its Indiana manufacturing sites

Eli Lilly and Novo Nordisk are preparing to launch high-dose obesity treatments in the South Korean market

Financial disclosure reveals Donald Trump invested in Eli Lilly in Q1 2026, coinciding with the government's push for favorable weight-loss drug policies.

UnitedHealth Group Faces Profit Pressure Amid Rising Medical Costs and Membership Structure Changes

Eli Lilly Completes Key Drug Interaction Study for its KRAS Inhibitor, Olomorasib

New report shows Eli Lilly and Novo Nordisk dominate GLP-1 drug citations in AI tools

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

Canada Approves Generic Version of Novo Nordisk's Ozempic, Potentially an Indirect Positive for Lilly

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Barclays Offers Structured Notes Linked to UnitedHealth Group Stock

Institutional Investor Larson Financial Group LLC Reduces Stake in Eli Lilly

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

MRVL

SNDK

QCOM

Marvell Tech(MRVL) rose 4.34%, with a trading turnover 4.3 Billion USD, and a year-to-date rose 107.7%. Sandisk(SNDK) rose 3.77%, with a trading turnover 17.8 Billion USD, and a year-to-date rose 482.7%. Vertiv(VRT) fell 5.03%, with a trading turnover 2.9 Billion USD, and a year-to-date rose 99.2%. BlackRock(BLK) fell 4.57%, with a trading turnover 1.1 Billion USD, and a year-to-date fell 2.6%.

- The Nasdaq Composite Index decreased by 0.84%, with a year-to-date gain of 11.3%.  
- Meanwhile, the S&P 500 fell by 0.67% and the Dow Jones dropped by 0.65%, recording year-to-date increases of 7.4% and 2.7%, respectively.  
- Notable stock movements include Marvell Technology rising by 4.34% and Sandisk increasing by 3.77% year-to-date, while Vertiv and BlackRock saw declines of 5.03% and 4.57%.

Top Gainers&Losers

Marvell Tech

Sandisk

Mizuho Financial

Eli Lilly

Vertiv

BlackRock

Newmont

Qualcomm

AppLovin

Top 5 US Stock Gainers/Losers (>100B) (5.19)

ABBV

AbbVie Inc. (ABBV) shares rose 2.08% to $213.76 on a challenging trading day for the market, outperforming competitors like Johnson & Johnson and Pfizer. The stock ended 12.68% below its 52-week high of $244.81. Trading volume reached 7.1 million, surpassing the 50-day average of 6.9 million.

MarketWatch Automated

Abbvie

VG Health

VanEck Biotech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

iShares US Pharma

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

S&P 500

Dow Jones Industrial Average

Johnson & Johnson

Pfizer

Amgen

Factset Research

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

CCEP

COKE

Coca-Cola, Procter & Gamble, and Johnson & Johnson are recognized as dividend kings, having raised dividends for over 50 years. Recent performance highlights include Coca-Cola's Zero Sugar growth, P&G surpassing revenue and profit forecasts, and J&J's pharma sales compensating for Stelara declines. These companies are attractive for long-term investors seeking stable income and potential capital gains.

- Three companies, Coca-Cola, Procter & Gamble, and Johnson & Johnson, have increased their dividends for over 50 years, marking them as reliable income stocks.  
- Recent performance highlights include Coca-Cola's growth in Zero Sugar sales, P&G surpassing revenue and profit expectations, and J&J's pharmaceutical sales compensating for declines in Stelara.  
- These Dividend Kings provide steady income and potential capital gains, making them attractive to long-term investors focused on stability.

Coca-Cola Europacific Partners

Coca Cola

Coca-Cola Bottling

Procter & Gamble

SPDR FD Consumer Staples

ISHRS S&Pp Glb Cons Staple

iShares US Consumer Staples ETF

VG Consumer Stap

Motley Fool names Coca-Cola, P&G, J&J as 20-year dividend kings

NVDA

Government ethics disclosures reveal Eric Trump made 3,642 stock transactions worth up to $750 million in early 2026, with some trades in Nvidia and Eli Lilly occurring just before favorable administration actions, raising conflict-of-interest concerns. Despite Eric Trump's denial that family members direct trades, lawmakers point to signed disclosures that contradict his statements.

- Government ethics disclosures indicate that Trump made 3,642 stock transactions valued up to $750 million in early 2026, with many involving specific companies.  
- Some trades, particularly in Nvidia and Eli Lilly, happened shortly before government actions that benefited those companies, raising conflict-of-interest concerns.  
- Despite Eric Trump's claims that family members do not direct trades, signed disclosures reveal individual stock purchases that contradict these assertions.

NVIDIA

NVIDIA Corporation

Eric Trump denial challenged by filings showing timed stock buys

ELIL

LLYX

Donald Trump disclosed stock purchases of up to $680,000 in Eli Lilly as Medicare initiatives advanced GLP-1 drug coverage. The investments coincided with policies benefiting the drugmaker's obesity treatments. Trump's purchases also included shares in West Pharmaceutical Services, valued between $250,000 and $500,000. A spokesperson stated that his investments are managed independently by third-party institutions. Eli Lilly shares rose 2.73% to $1015.09, gaining 9.4% over the past month.

benzinga_article

West Pharmaceutical

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

Thomson Reuters

Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report

In today's trading, U.S. semiconductor stocks like Nvidia and AMD saw significant declines, while the healthcare sector, led by Eli Lilly and AbbVie, showed gains. The market sentiment is cautious due to concerns over the global chip shortage, but optimism in healthcare suggests a shift in investor interest. Recommendations include increasing healthcare allocations and considering semiconductor stocks for risk-tolerant investors, emphasizing the importance of diversification.

- The U.S. stock market showed mixed results, with technology stocks, notably semiconductors like Nvidia and AMD, experiencing declines amid pressures in the industry.  
- In contrast, the healthcare sector thrived with gains from Eli Lilly and AbbVie due to strong earnings and positive clinical news, attracting investor interest.  
- Strategic recommendations suggest investors increase healthcare sector allocations while considering the semiconductor weaknesses as potential buying opportunities for those willing to endure short-term fluctuations.

Investinglive

T-Rex 2X Inverse NVIDIA Daily Target ETF

Direxion Daily NVDA Bear 1X ETF

Direxion Daily NVDA Bull 2X Shares

GraniteShares 2x Long NVDA Daily ETF

Direxion Semicon Bear 3X

Direxion Daily AMD Bear 1X Shares

Direxion Daily AMD Bull 2X Shares

AXS 1.5X NVDA Bear Daily ETF

GraniteShares 2x Long AMD Daily ETF

GraniteShares 2x Short NVDA Daily ETF

Intel

Tech turmoil: Semiconductor stocks slide, healthcare finds footing

President Trump purchased $680,000 in Eli Lilly (LLY) stock around the FDA's approval of a new weight-loss pill. The timing of these trades coincides with favorable government decisions benefiting Lilly, including a Medicare reimbursement pilot program for GLP-1 drugs. Trump's stock trades, disclosed in ethics forms, include various investments across sectors, but Lilly's trades stand out due to their potential impact on the company's revenue growth, projected to exceed $80 billion in 2026.

Tip Ranks

Microsoft

Boeing

Target

Chipotle Mexican Grill

Citigroup

Toronto Dominion Bank

Boeing Company

CITIGROUP INC 6.250 NON CUM SER II PFD WI

President Trump Bought Eli Lilly Stock (LLY) as Government Approved Weight-Loss Pill

AbbVie and CVS Health appear expensive with trailing P/E multiples over 40, but non-recurring expenses inflate these figures. AbbVie’s forward P/E is 15, while CVS Health’s is 13, indicating they may be undervalued. AbbVie faced a significant drop in net income due to a $2.7 billion charge, while CVS reported a $4 billion loss from goodwill impairment. Both companies show potential for better performance, making them attractive investment options despite their current valuations.

nasdaq

CVS Health

2 Stocks That Are Much Cheaper Than They Look

PILL

The Supreme Court declined to hear appeals from six drugmakers against Medicare's drug price negotiations. This decision is projected to save patients $1.5 billion and Medicare $6 billion in the first year. Ongoing legal challenges in lower courts may lead to future Supreme Court reviews.

Bristol Myers Squibb

Direxion Pharma & Medical Bull 3X

Supreme Court rejects drugmakers’ bid to halt Medicare price talks

Merck has launched a Hypertension Risk Checker to raise awareness about elevated resting heart rates as a potential cardiovascular risk, coinciding with World Hypertension Day. The initiative aims to encourage proactive heart health management, addressing the fact that 1.4 billion people globally live with high blood pressure, many unaware of their condition. Merck emphasizes the importance of early detection and education in managing heart health, marking four decades of commitment to cardiovascular care in the Gulf region.

Zawya

Merck

Merck KGaA

ZAWYA: Merck marks World Hypertension Day with launch of Hypertension Risk Checker

Direxion Healthcare Bull 3X(CURE.US)

Top 5 US Stock Gainers/Losers (>100B) (5.19)

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

Motley Fool names Coca-Cola, P&G, J&J as 20-year dividend kings

Eric Trump denial challenged by filings showing timed stock buys

Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report